Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796767 · ClinicalTrials.gov registry record · Phase 2
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03796767: Active Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by University of Utah.
NCT03796767 is a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 20 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796767, a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as oligometastasectomy, may remove tumor cells that have spread to other parts of the body. Surgery and radiation therapy may work better in treating patients with prostate cancer that has come back or spread to other parts of the body.
Primary Outcome
The primary outcome measure will report the count of patients achieving a PSA decline \>= 50% at 6 months after completion of treatment (salvage + - adjuvant). Prostate-Specific Antigen (PSA) is a protein produced by tissue in the prostate. An elevated PSA value can be a sign of prostate cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Hypofractionated Radiation Therapy
- RADIATION Intensity-Modulated Radiation Therapy
- PROCEDURE Metastasectomy
Study Locations (1)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03796767 still lists
NCT03796767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower).
The record links to 6 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03796767 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03796767 about?
NCT03796767 is a clinical study titled "Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer". This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as oligometastasectomy,...
What is the current status of trial NCT03796767?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-09-09. Estimated completion is 2026-06-30.
What conditions does trial NCT03796767 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Oligometastasis, Metastatic Malignant Neoplasm in the Lymph Nodes.
What interventions are being tested in trial NCT03796767?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Hypofractionated Radiation Therapy (RADIATION), Intensity-Modulated Radiation Therapy (RADIATION), Metastasectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03796767?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796767 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03796767's enrollment target sits among peer trials
20 85th of 99 higher than 12 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI